LYON, France, May 20, 2013 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today new long term data demonstrating high rates of both cancer-specific and overall survival of patients treated with high-intensity focused ultrasound (HIFU). The study led by Drs. Sebastien Crouzet and Albert Gelet of Edouard Herriot Hospital, located in Lyon, France evaluated the morbidity and long term oncologic outcomes of primary HIFU therapy for localized prostate cancer. The prospective, single-arm, single-institution cohort study was electronically published by European Urology, the official journal of the European Association of Urology. The study, titled "Whole-gland Ablation of Localized Prostate Cancer with High-intensity Focused Ultrasound: Oncologic Outcomes and Morbidity in 1002 Patients," examined 1002 patients treated from 1997 to 2009 and followed through 2012. Overall, the ten year cancer-specific survival rate was 97%. Stratified by risk group, the cancer-specific survival was 99%, 98% and 92% for men with low, intermediate, and high-risk disease, respectively. The overall metastasis-free rate was 94% and was 99%, 95%, and 86% for low, intermediate, and high-risk groups, respectively. Sebastien Crouzet, M.D., Urologist at Edouard Herriot Hospital, Lyon, France, said, "We are proud to have published the largest long-term study of HIFU. It is a minimally invasive therapeutic option with encouraging cancer-specific survival rates in patients with localized prostate cancer. The 10-year prostate cancer survival rates and metastases free survival rates were low, and the morbidity acceptable. We continue to routinely prescribe HIFU to our patients as standard of care. These results should encourage other centers worldwide to do so as well." John Rewcastle, Ph.D., Medical Director of EDAP-TMS, commented, "The Lyon study is the third peer reviewed publication this year reporting 10 year cancer specific survival and metastates free survival rates following Ablatherm HIFU. Significantly, this is a prospective study and is the largest of the three. Following patients long enough to generate 10 year cancer specific survival rates is a formidable task and no other ablative therapy for prostate cancer has ever produced such a study, let alone three. These studies not only clearly demonstrate durable cancer control but taken together they also make evident the reproducibility of the procedure.